treatment
viral
infect
children
primarili
support
sever
viral
ill
signific
secondari
complic
requir
treatment
intens
care
unit
may
occur
immunocompromis
patient
also
infant
children
previous
healthi
antivir
agent
specif
activ
certain
respiratori
virus
herpesvirus
enter
virus
avail
new
drug
develop
use
pediatr
patient
subject
activ
research
clinician
knowledg
mechan
action
spectrum
activ
side
effect
drug
import
tool
judici
use
treatment
critic
ill
child
c
hildren
suscept
infect
caus
varieti
viral
pathogen
result
wide
spectrum
diseas
manifest
infant
children
previous
healthi
may
viral
ill
sever
enough
requir
care
pediatr
intens
care
unit
viral
infect
might
result
respiratori
failur
eg
caus
respiratori
syncyti
viru
rsv
influenza
parainfluenza
adenoviru
alter
mental
statu
associ
enceph
mening
eg
herp
simplex
viru
hsv
enteroviru
arboviru
dehydr
shock
sever
gastroenter
eg
rotaviru
enteroviru
hepat
liver
failur
hepat
virus
b
c
multiorgan
involv
immunocompromis
children
suscept
common
virus
develop
sever
local
dissemin
diseas
virus
includ
member
herpesviru
famili
cytomegaloviru
cmv
epsteinbarr
viru
ebv
varicellazost
viru
vzv
review
describ
antivir
agent
current
avail
use
treatment
common
viral
infect
critic
ill
children
treatment
human
immunodefici
viru
hiv
infect
beyond
scope
review
tabl
summar
import
caus
viral
ill
children
admit
intens
care
unit
current
option
treatment
prophylaxi
viral
respiratori
infect
lead
caus
morbid
mortal
signific
econom
expens
throughout
world
unit
state
acut
viral
respiratori
diseas
requir
medic
attent
percent
children
younger
year
almost
percent
year
age
children
hospit
acut
respiratori
ill
rsv
pathogen
frequent
encount
follow
parainfluenza
influenza
b
virus
pathogenesi
diseas
caus
virus
involv
direct
epitheli
cell
injuri
bronchiol
edema
mucu
plug
airway
import
pathogen
includ
adenoviru
rhinoviru
respiratori
coronavirus
infect
virus
may
result
sever
lower
respiratori
tract
diseas
may
precipit
acut
exacerb
underli
pulmonari
condit
asthma
cystic
fibrosi
recent
survey
percent
episod
acut
asthma
school
children
associ
respiratori
viru
infect
rhinoviru
account
percent
isol
treatment
viral
infect
essenti
support
number
efficaci
antivir
drug
current
avail
limit
tabl
aerosol
ribavirin
use
treat
rsv
infect
oral
amantadin
rimantadin
avail
treatment
prophylaxi
influenza
infect
newer
agent
activ
influenza
b
virus
neuraminidas
inhibitor
becom
avail
recent
licens
use
children
yet
newer
compound
activ
paramyxovirus
rhinovirus
picornavirus
investig
proven
efficaci
drug
treatment
adenoviru
infect
shown
ribavirin
synthet
nucleosid
analogu
guanosin
inosin
convert
cellular
enzym
activ
monophosph
triphosph
form
exact
mechan
action
unknown
ribavirin
exhibit
vitro
activ
mani
rna
dna
virus
report
clinic
efficaci
rsv
influenza
b
virus
hantaviru
lassa
fever
viru
aerosol
ribavirin
current
indic
treat
rsv
lower
respiratori
tract
infect
select
highrisk
popul
condit
associ
high
risk
rsv
infect
includ
complic
congenit
heart
diseas
underli
chronic
lung
diseas
primari
acquir
immunosuppress
prematur
age
less
week
certain
debilit
condit
eg
neuromuscular
diseas
sever
ill
requir
mechan
ventil
although
administr
earli
cours
rsv
diseas
immunocompromis
highrisk
patient
may
benefici
efficaci
ribavirin
critic
ill
children
previous
healthi
prove
ribavirin
licens
treatment
influenza
anecdot
report
indic
efficaci
measl
adenoviru
infect
aerosol
intraven
form
control
trial
perform
date
oral
ribavirin
combin
interferon
alfa
indic
treat
hepat
c
combin
also
inhibit
replic
subacut
scleros
panenceph
viru
infect
vitro
result
improv
surviv
infect
hamster
clinic
studi
perform
administr
ribavirin
inhal
requir
use
small
particl
aerosol
gener
spag
deliveri
rate
lmin
daili
recommend
dose
gd
administ
standard
concentr
mgml
hour
higher
concentr
mgml
shorter
period
eg
h
three
timesd
total
durat
day
given
children
requir
mechan
ventil
aerosol
ribavirin
significantli
affect
respiratori
system
mechan
howev
malfunct
ventil
deliveri
system
occur
drug
crystal
precipit
potenti
side
effect
includ
induct
bronchospasm
headach
rash
conjunct
patient
caretak
use
system
load
mainten
dose
necessari
ribavirin
caus
anemia
result
extravascular
hemolysi
low
dose
bone
marrow
suppress
high
dose
hyperbilirrubinemia
teratogen
document
anim
speci
resist
describ
rsv
parainfluenza
measl
virus
belong
paramyxoviru
famili
virus
contain
two
major
surfac
glycoprotein
receptor
bind
protein
facilit
attach
host
cell
fusion
protein
requir
releas
genomecontain
nucleocapsid
cell
cytoplasm
activ
peptid
deriv
specif
region
within
transmembran
fusion
protein
rsv
parainfluenza
viru
identifi
activ
peptid
exhibit
antivir
activ
paramyxovirus
vitro
rsv
vivo
cotton
rat
model
potenti
develop
synthet
activ
peptid
paramyxovirus
exist
similar
compound
develop
amantadin
hydrochlorid
deriv
rimantadin
primari
symmetr
amin
interfer
transmembran
transport
hydrogenion
h
initi
influenza
membran
protein
inhibit
uncoat
replic
human
influenza
viru
subtyp
effect
influenza
b
virus
oral
formul
shown
efficaci
reduc
sever
durat
influenza
ill
administ
within
first
hour
onset
symptom
licens
unit
state
prophylaxi
treatment
influenza
infect
rimantadin
approv
food
drug
administr
fda
use
children
frequent
prefer
exhibit
fewer
side
effect
amantadin
longer
halflif
allow
onceaday
dose
side
effect
similar
induc
antihistamin
nausea
vomit
drowsi
difficulti
concentr
agit
may
induc
seizur
individu
histori
seizur
disord
resist
drug
develop
frequent
rapidli
therapi
singl
amino
acid
mutat
rna
sequenc
encod
influenza
protein
phenomenon
describ
hospit
pediatr
popul
concern
particularli
risk
transmiss
resist
strain
influenza
suscept
patient
within
hospit
unit
intens
care
unit
outbreak
situat
within
hospit
unit
amantadin
rimantadin
use
prophylaxi
children
risk
immun
inactiv
influenza
vaccin
neuraminidas
viral
enzym
cleav
termin
sialic
acid
residu
glycoconjug
enabl
releas
influenza
virus
infect
cell
prevent
viral
aggreg
inactiv
respiratori
mucu
enzym
activ
site
present
highli
conserv
surfac
influenza
b
virus
two
neuraminidas
inhibitor
activ
influenza
b
avail
clinic
use
inhal
zanamavir
oral
oseltamivir
ethyl
ester
prodrug
activ
compound
sialic
acid
analogu
zanamavir
estim
bioavail
percent
lower
respiratori
airway
administ
inhal
mouth
intranas
spray
poor
oral
bioavail
rapid
renal
clearanc
intraven
administr
preclud
use
rout
inhal
zanamavir
well
toler
effect
prevent
infect
febril
ill
anim
human
experiment
influenza
infect
recent
random
placebocontrol
trial
zanamavir
administ
daili
influenza
season
healthi
adult
volunt
percent
efficaci
prevent
cultureconfirm
clinic
influenza
percent
efficaci
prevent
cultureconfirm
febril
ill
clinic
studi
investig
use
zanamavir
postexposur
prophylaxi
institut
prevent
nosocomi
influenza
administ
within
first
hour
ill
ambulatori
adult
acut
influenza
zanamavir
reduc
durat
symptom
day
similar
result
observ
patient
young
year
underli
lung
diseas
use
nebul
zanamavir
hospit
patient
influenza
lower
respiratori
tract
diseas
studi
control
clinic
trial
nebul
prepar
given
patient
receiv
mechan
ventil
compassion
use
protocol
inhal
zanamavir
approv
treatment
influenza
b
infect
patient
year
age
older
zanamavir
potenti
role
prophylact
agent
nonimmun
highrisk
individu
studi
latter
popul
necessari
use
zanamavir
children
deserv
consider
well
particularli
treatment
drug
associ
lower
incid
middl
ear
pressur
abnorm
influenza
ill
current
method
drug
deliveri
might
problemat
younger
patient
oseltamivir
prodrug
potent
carbocycl
transit
state
analogu
inhibitor
influenza
neuraminidas
advantag
good
oral
bioavail
long
plasma
halflif
hour
allow
less
frequent
dose
activ
compound
provid
protect
experiment
influenza
anim
human
studi
natur
infect
healthi
adult
efficaci
given
oncedaili
dose
influenza
season
use
treatment
within
first
hour
onset
ill
oseltamivir
reduc
sever
durat
influenza
symptom
day
use
oseltamivir
highrisk
popul
children
studi
resist
neuraminidas
inhibitor
occur
mutat
amino
acid
substitut
either
two
major
surfac
glycoprotein
hemagglutinin
neuraminidas
albeit
rare
phenomenon
occur
vivo
immunocompromis
child
influenza
b
pneumonia
day
treatment
zanamavir
human
rhinovirus
belong
picornavirida
famili
picornavirus
known
caus
conjunct
lower
respiratori
tract
diseas
acut
gastroenter
asept
mening
enceph
addit
common
cold
current
antivir
agent
avail
treat
diseas
caus
picornavirus
potenti
drug
develop
irrevers
peptidomimet
inhibitor
proteas
enzym
present
rhinovirus
sever
relat
picornavirus
respons
cleavag
viral
precursor
polyprotein
structur
enzymat
protein
vitro
found
potent
inhibit
replic
rhinoviru
serotyp
coxsackievirus
enteroviru
echoviru
dosedepend
fashion
formul
intranas
administr
develop
clinic
studi
expect
near
futur
pleconaril
investig
compound
inhibit
viral
replic
show
vitro
activ
picornavirus
pleconaril
bind
capsid
virus
inhibit
attach
viru
uncoat
readili
absorb
oral
rout
bioavail
percent
reach
higher
drug
concentr
mening
liver
nasal
epithelium
plasma
lipophil
properti
studi
experiment
respiratori
infect
placebocontrol
studi
viral
mening
adult
children
pleconaril
shown
reduc
sever
durat
symptom
administ
within
hour
onset
ill
control
clinic
trial
pleconaril
treatment
rhinoviru
diseas
enterovir
mening
children
progress
human
herpesvirus
common
caus
mucocutan
infect
immunocompet
immunocompromis
children
import
caus
sporad
viral
central
nervou
system
infect
follow
frequenc
season
virus
enterovirus
arbovirus
herpesvirus
uncommon
caus
sever
lifethreaten
condit
previous
healthi
children
develop
complic
dissemin
initi
local
infect
vzv
immunocompromis
children
also
suscept
extens
diseas
caus
herpesvirus
cmv
ebv
human
herpesviru
numer
antivir
agent
avail
treatment
prophylaxi
herpesviru
infect
gener
agent
categor
two
major
class
nucleosid
analogu
includ
antiherpesviru
drug
pyrophosp
analogu
foscarnet
tabl
nucleosid
analogu
requir
convers
monophosph
diphosph
triphosph
form
cellular
viral
kinas
select
inhibit
viral
replic
foscarnet
acyclovir
synthet
acycl
purin
nucleosid
analogu
guanosin
valacyclovir
lvalyl
ester
acyclovir
three
five
time
bioavail
acyclovir
hydrolysi
valacyclovir
acyclovir
occur
intestin
wall
liver
acyclovir
catalyz
herpesviru
thymidin
kinas
acyclovir
monophosph
transform
activ
compound
acyclovir
triphosph
cellular
kinas
activ
drug
inhibit
viral
dna
polymeras
act
immedi
dna
chain
termin
acyclovir
activ
sensit
viru
twofold
less
suscept
vzv
requir
higher
dose
hsv
limit
activ
cmv
ebv
lack
thymidin
kinas
oral
topic
intraven
prepar
acyclovir
avail
efficaci
treatment
children
hsv
mucocutan
diseas
enceph
neonat
infect
primari
recurr
vzv
infect
intraven
administr
requir
treat
invas
diseas
prevent
dissemin
mucocutan
infect
immunocompromis
host
administr
earli
cours
diseas
benefici
valacyclovir
avail
tablet
form
safeti
effect
administ
intraven
acyclovir
crystal
precipit
renal
tubul
minim
slow
infus
rate
ensur
adequ
hydrat
side
effect
includ
local
phlebiti
elev
blood
urea
nitrogen
bun
serum
creatinin
level
neutropenia
nonspecif
gastrointestin
symptom
nausea
vomit
diarrhea
encephalopath
chang
obtund
seizur
adjust
dose
requir
impair
renal
function
resist
acyclovir
occur
mutat
result
defici
alter
thymidin
kinas
viral
dna
polymeras
resist
like
occur
prolong
exposur
suboptim
dose
immunocompromis
patient
foscarnet
cidofovir
altern
acyclovirresist
hsv
vzv
famciclovir
synthet
acycl
guanin
deriv
prodrug
penciclovir
famciclovir
readili
absorb
oral
administr
convert
activ
triphosph
form
penciclovir
viral
thymidin
kinas
like
acyclovir
unlik
acyclovir
penciclovir
oblig
dna
chain
termin
effect
inhibit
dna
chain
elong
also
exhibit
less
power
inhibit
viral
dna
polymeras
howev
famciclovir
higher
oral
bioavail
longer
intracellular
halflif
ensur
prolong
antivir
activ
allow
lower
less
frequent
dose
clinic
indic
advers
event
mechan
resist
drug
similar
acyclovir
valacyclovir
safeti
efficaci
data
avail
children
trifluridin
idoxuridin
thymidin
nucleosid
analogu
use
topic
treatment
hsv
infect
primari
keratoconjunct
recurr
epitheli
kerat
requir
phosphoryl
activ
triphosph
form
signific
side
effect
toxic
local
irrit
corneal
conjunctiv
edema
increas
intraocular
pressur
photophobia
trifluridin
licens
use
unit
state
compound
also
use
topic
treatment
acyclovirresist
chronic
mucocutan
genit
hsv
infect
hivinfect
patient
vidarabin
adenin
arabinosid
araa
antivir
activ
vaccinia
viru
vzv
intraven
vidarabin
rapidli
deamin
vivo
less
activ
compound
arahypoxanthin
associ
signific
toxic
limit
use
trifluridin
prefer
treatment
hsv
keratoconjunct
vidarabin
caus
signific
local
eye
irrit
resist
agent
occur
clinic
set
ganciclovir
nucleosid
analogu
guanin
undergo
transform
ganciclovir
monophosph
two
viralspecif
enzym
phosphotransferas
encod
gene
cmv
thymidin
kinas
hsv
activ
triphosph
form
accomplish
cellular
kinas
ganciclovir
inhibit
viral
dna
synthesi
directli
termin
viral
dna
elong
competit
inhibit
dna
polymeras
although
ganciclovir
vitro
activ
hsv
vzv
time
potent
cmv
ganciclovir
indic
treatment
cmv
retin
enceph
pneumon
esophag
hepat
coliti
use
prophylaxi
cmv
retin
select
cmvseroposit
immunocompromis
patient
ie
bone
marrow
solid
organ
transplant
recipi
limit
data
children
suggest
safeti
efficaci
similar
adult
combin
ganciclovir
cmv
immun
globulin
intraven
use
treatment
prophylaxi
cmv
diseas
immunocompromis
patient
ganciclovir
also
may
role
prophylaxi
ebv
lymphoprolif
diseas
transplant
recipi
use
ganciclovir
congenit
cmv
diseas
investig
routin
recommend
antivir
treatment
popul
unlik
effect
tissu
injuri
occur
antenat
signific
toxic
commonli
occur
intraven
administr
ganciclovir
includ
bone
marrow
depress
granulocytopenia
anemia
thrombocytopenia
elev
hepat
transaminas
serum
bun
creatinin
level
less
frequent
nonspecif
gastrointestin
complaint
headach
rash
dose
adjust
requir
impair
renal
function
concomit
use
nephrotox
drug
increas
ganciclovir
nephrotox
immunocompromis
patient
often
requir
prolong
therapi
ganciclovir
increas
chanc
toxic
develop
resist
resist
occur
mutat
gene
encod
viral
dna
polymeras
cmv
phosphotransferas
hsv
thymidin
kinas
therefor
ganciclovirresist
cmv
may
suscept
treatment
acyclovir
requir
use
agent
differ
mechan
action
cidofovir
foscarnet
cidofovir
new
acycl
nucleosid
monophosph
deriv
presenc
phosphon
group
initi
phosphoryl
viralspecif
enzym
requir
cidofovir
phosphoryl
host
cell
enzym
activ
diphosph
form
select
inhibit
viral
dna
polymeras
competit
inhibit
dna
chain
termin
cidofovir
potent
inhibitor
viral
replic
activ
cmv
herpesvirus
includ
hsv
vzv
ebv
given
initi
phosphoryl
viral
enzym
bypass
cidofovir
drug
choic
acyclovirresist
hsv
gancicloviror
foscarnetresist
cmv
activ
diphosph
form
long
intracellular
halflif
allow
long
interv
administr
dose
weekli
cidofovir
addit
synergist
cmv
vitro
combin
acyclovir
ganciclovir
foscarnet
signific
side
effect
nephrotox
proxim
tubular
dysfunct
reduc
oral
probenicid
adequ
hydrat
treatment
advers
reaction
includ
neutropenia
peripher
neuropathi
ocular
hypotonia
viral
resist
confer
mutat
dna
polymeras
shown
vitro
occur
patient
treat
cidofovir
foscarnet
foscarnet
trisodium
phosphonoform
organ
analogu
inorgan
pyrophosph
phosphoryl
viral
host
cell
kinas
requir
activ
compound
mechan
action
prevent
elong
dna
chain
select
inhibit
pyrophosph
bind
site
viral
dna
polymeras
retrovir
revers
transcriptas
concentr
inhibit
cellular
dna
polymeras
foscarnet
antivir
activ
includ
acyclovirresist
strain
vzv
cmv
includ
ganciclovirresist
strain
ebv
hepat
b
viru
foscarnet
current
indic
treatment
cmv
retin
hivinfect
patient
acyclovirresist
hsv
infect
immunocompromis
host
acyclovirresist
vzv
also
treat
success
foscarnet
use
limit
occurr
significantli
advers
event
occur
ganciclovir
intraven
administr
foscarnet
commonli
result
phlebiti
nausea
diarrhea
anemia
granulocytopenia
nephrotox
electrolyt
disord
hypocalcemia
hypokalemia
hypomagnesemia
hypophosphatemia
hyperphosphatemia
seizur
excret
drug
urin
may
result
genit
ulcer
concomit
administr
nephrotox
drug
minim
serum
calcium
level
monitor
close
patient
receiv
intraven
pentamidin
anim
studi
foscarnet
shown
affect
develop
tooth
enamel
bone
resist
foscarnet
may
develop
mutat
viral
dna
polymeras
acyclovirresist
hsv
ganciclovirresist
cmv
virus
mutat
might
also
develop
resist
foscarnet
viral
infect
caus
gastroenter
selflimit
requir
support
therapi
hepat
virus
caus
acut
chronic
diseas
children
children
younger
year
account
percent
patient
primari
hepat
b
viru
hbv
infect
year
epidemiolog
hepat
c
viru
hcv
infect
children
less
well
character
unit
state
incid
like
similar
less
major
children
hbv
hcv
infect
asymptomat
howev
percent
children
percent
neonat
infect
hbv
persist
infect
major
children
infect
hcv
chronic
infect
may
progress
cirrhosi
virus
associ
develop
hepatocellular
carcinoma
risk
factor
hbv
hcv
infect
includ
parenter
exposur
blood
product
parenter
drug
use
hemoglobinopathi
heterosexu
homosexu
activ
matern
infect
pregnanc
numer
potenti
drug
avail
treatment
hepat
b
c
tabl
interferon
alfa
modestli
efficaci
increas
efficaci
use
combin
ribavirin
interferon
cytokin
releas
virusinfect
host
cell
uninfect
cell
acquir
resist
rna
dna
virus
bind
intern
interferon
although
exact
mechan
action
total
understood
interferon
activ
cellular
mechan
induc
releas
enzym
caus
degrad
viral
mrna
inhibit
viral
protein
synthesi
recombin
interferon
licens
unit
state
treatment
chronic
hbv
infect
adult
children
subcutan
administr
three
time
week
month
result
normal
liver
transaminas
level
seroconvers
presenc
antibodi
hepat
b
e
antigen
hbeab
absenc
hepat
b
e
antigen
hbeag
percent
adult
patient
control
clinic
trial
suggest
similar
respons
rate
rang
children
live
western
countri
lower
respons
rate
asian
children
respons
rate
lower
acquir
hbv
neonat
period
higher
higher
dose
interferon
respons
rate
defin
absenc
hcv
dna
serum
similar
interferon
alfa
use
treatment
adult
hepat
c
relaps
rate
percent
occur
complet
therapi
net
persist
respons
rate
nonrespond
show
improv
repeat
treatment
higher
dose
longer
durat
therapi
clinic
studi
children
limit
hbv
similar
respons
relaps
rate
observ
children
hcv
use
combin
oral
administ
ribavirin
persist
respons
rate
interferon
alfa
treatment
hcv
increas
percent
interferon
alfa
might
also
use
treatment
ebv
lymphoproliph
diseas
side
effect
interferon
therapi
frequent
transient
includ
fever
headach
malais
thrombocytopenia
leukopenia
less
frequent
alopecia
prolong
fatigu
depress
may
occur
need
repeat
parenter
administr
lack
sustain
respons
patient
impli
adequ
select
subject
receiv
treatment
interferon
case
hbv
better
respons
rate
observ
nonasian
children
infect
acquir
beyond
neonat
period
mild
pretreat
elev
liver
enzym
liver
histolog
lower
baselin
serum
hbv
dna
hepat
b
core
antigen
hbcag
concentr
nucleosid
analogu
lamivudin
famciclovir
adefovir
tenofovir
inhibit
hbv
replic
vitro
inhibit
dna
polymeras
although
agent
efficaci
experiment
anim
studi
reduc
hbv
dna
level
patient
chronic
hbv
infect
longterm
treatment
requir
turn
associ
develop
resist
mutat
hbv
dna
polymeras
except
adefovir
combin
therapi
investig
viral
infect
common
caus
morbid
pediatr
major
children
viral
ill
requir
hospit
howev
sever
ill
complic
secondari
bacteri
infect
requir
treatment
pediatr
intens
care
unit
also
occur
infant
young
children
patient
certain
underli
condit
commonli
admit
intens
care
unit
prevent
immun
possibl
influenza
hepat
b
viru
infect
encourag
particularli
highrisk
popul
passiv
prophylaxi
intraven
immunoglobulin
highrisk
group
avail
rsv
cmv
monoclon
antibodi
product
avail
rsv
well
number
drug
becom
avail
treat
sever
viral
infect
children
increas
howev
import
keep
mind
efficaci
might
limit
need
administr
earli
cours
diseas
therefor
adequ
diagnost
frequent
toxic
develop
resist
adequ
support
therapi
continu
cornerston
treatment
sever
viral
infect
children
knowledg
current
avail
antivir
agent
particular
indic
side
effect
along
select
judici
use
drug
enhanc
clinician
capabl
achiev
success
outcom
critic
ill
child
